DelveInsight’s “Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Seborrhoeic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Seborrhoeic Dermatitis Market Forecast
Some of the key facts of the Seborrhoeic Dermatitis Market Report:
The Seborrhoeic Dermatitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In October 2024, Arcutis Biotherapeutics’ subsidiary, Arcutis Canada, has obtained Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3% for treating seborrheic dermatitis in patients aged nine and older. This marks the second international approval for ZORYVE, providing a new treatment option for over two million Canadians affected by this chronic skin condition. The approval was supported by positive findings from the pivotal Phase III STRATUM study, along with data from a Phase II long-term open-label extension trial and a Phase I pharmacokinetic study.
According to Sessevile et al. (n.d.), seborrheic dermatitis is more common in people with HIV infection, where it may present as a presenting symptom. According to estimates, the prevalence ranges from up to 85% among people with acquired immunodeficiency syndrome (AIDS) and around 35% among those with early HIV infection
According to Berl et al., dandruff, a non-inflammatory form of seborrheic dermatitis, is more common than 5% of seborrheic dermatitis worldwide
The current approach to treating seborrheic dermatitis is to loosen scale, lessen swelling and inflammation, and stop itching. The major objectives of the suggested treatments for seborrheic dermatitis are to eliminate the disease’s outward symptoms. A few preventative regimens have been identified because seborrheic dermatitis has been linked to sporadic relapses over several years
Key Seborrhoeic Dermatitis Companies: Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others
Key Seborrhoeic Dermatitis Therapies: ARQ 154, Omiganan, K40a, ASF1057, Azelaic Acid 15% Gel, ARQ-154, SEBORRHEAMEDIS Face Cream, PAC-14028, K301, Elidel, Ruxolitinib, and others
The Seborrhoeic Dermatitis epidemiology based on gender analyzed that males are most commonly affected in case of Seborrhoeic Dermatitis
The Seborrhoeic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Seborrhoeic Dermatitis pipeline products will significantly revolutionize the Seborrhoeic Dermatitis market dynamics.
Seborrhoeic Dermatitis Overview
Seborrheic dermatitis is a common, chronic skin condition characterized by red, inflamed skin with greasy or flaky white or yellow scales. It most commonly affects areas of the body where sebaceous (oil-producing) glands are most active, such as the scalp, face, ears, eyebrows, and chest.
Get a Free sample for the Seborrhoeic Dermatitis Market Report:
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
Seborrhoeic Dermatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Seborrhoeic Dermatitis Epidemiology Segmentation:
The Seborrhoeic Dermatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Seborrhoeic Dermatitis
Prevalent Cases of Seborrhoeic Dermatitis by severity
Gender-specific Prevalence of Seborrhoeic Dermatitis
Diagnosed Cases of Episodic and Chronic Seborrhoeic Dermatitis
Download the report to understand which factors are driving Seborrhoeic Dermatitis epidemiology trends @ Seborrhoeic Dermatitis Epidemiology Forecast
Seborrhoeic Dermatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Seborrhoeic Dermatitis market or expected to get launched during the study period. The analysis covers Seborrhoeic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Seborrhoeic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Seborrhoeic Dermatitis Therapies and Key Companies
ARQ 154: Arcutis Biotherapeutics
Omiganan: Cutanea Life Sciences
K40a: Moberg Pharma AB
ASF1057: Astion Pharma A/S
Azelaic Acid 15% Gel: LEO Pharma
ARQ-154: Arcutis Biotherapeutics
Omiganan: Maruho Co., Ltd.
SEBORRHEAMEDIS Face Cream: Kamedis Ltd.
PAC-14028: Amorepacific Corporation
K301: Moberg Pharma AB
Elidel: Novartis
Ruxolitinib: Incyte Corporation
Discover more about therapies set to grab major Seborrhoeic Dermatitis market share @ Seborrhoeic Dermatitis Treatment Market
Seborrhoeic Dermatitis Market Strengths
The use of off-label branded and generic prescription medications targeted at individual symptoms of Seborrhoeic Dermatitis, including antiepileptics, antipsychotics, antidepressants and benzodiazepines
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Seborrhoeic Dermatitis
Seborrhoeic Dermatitis Market Opportunities
Challenges in diagnoses
Development of novel therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers
Scope of the Seborrhoeic Dermatitis Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Seborrhoeic Dermatitis Therapeutic Assessment: Seborrhoeic Dermatitis current marketed and Seborrhoeic Dermatitis emerging therapies
Seborrhoeic Dermatitis Market Dynamics: Seborrhoeic Dermatitis market drivers and Seborrhoeic Dermatitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Seborrhoeic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Seborrhoeic Dermatitis Market Access and Reimbursement
To know more about Seborrhoeic Dermatitis companies working in the treatment market, visit @ Seborrhoeic Dermatitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Seborrhoeic Dermatitis Market Report Introduction
2. Executive Summary for Seborrhoeic Dermatitis
3. SWOT analysis of Seborrhoeic Dermatitis
4. Seborrhoeic Dermatitis Patient Share (%) Overview at a Glance
5. Seborrhoeic Dermatitis Market Overview at a Glance
6. Seborrhoeic Dermatitis Disease Background and Overview
7. Seborrhoeic Dermatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Seborrhoeic Dermatitis
9. Seborrhoeic Dermatitis Current Treatment and Medical Practices
10. Seborrhoeic Dermatitis Unmet Needs
11. Seborrhoeic Dermatitis Emerging Therapies
12. Seborrhoeic Dermatitis Market Outlook
13. Country-Wise Seborrhoeic Dermatitis Market Analysis (2019–2032)
14. Seborrhoeic Dermatitis Market Access and Reimbursement of Therapies
15. Seborrhoeic Dermatitis Market Drivers
16. Seborrhoeic Dermatitis Market Barriers
17. Seborrhoeic Dermatitis Appendix
18. Seborrhoeic Dermatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: LasVegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
